Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis. Suh YJ, Lee B, Kim K, Jeong Y, et al. BMC Cancer 2022;22:346.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Suh YJ, Lee B, Kim K, Jeong Y, et al. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis. BMC Cancer 2022;22:346.
PMID: 35354431